| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Infections | 38 | 2023 | 316 | 6.690 |
Why?
|
| Papillomaviridae | 22 | 2018 | 125 | 4.230 |
Why?
|
| Liver Neoplasms | 17 | 2023 | 195 | 3.450 |
Why?
|
| Carcinoma, Hepatocellular | 15 | 2023 | 147 | 3.370 |
Why?
|
| Breast Neoplasms | 20 | 2023 | 1426 | 2.530 |
Why?
|
| Middle Aged | 79 | 2022 | 9642 | 1.970 |
Why?
|
| Aged | 66 | 2021 | 6448 | 1.850 |
Why?
|
| Neoplasms | 12 | 2023 | 1033 | 1.730 |
Why?
|
| Ovarian Neoplasms | 13 | 2023 | 303 | 1.720 |
Why?
|
| Cyanobacteria | 2 | 2023 | 23 | 1.710 |
Why?
|
| Female | 105 | 2023 | 19873 | 1.680 |
Why?
|
| Humans | 137 | 2023 | 34853 | 1.630 |
Why?
|
| Uterine Cervical Diseases | 6 | 2012 | 14 | 1.560 |
Why?
|
| Hawaii | 33 | 2022 | 1878 | 1.530 |
Why?
|
| Uterine Cervical Neoplasms | 10 | 2023 | 248 | 1.450 |
Why?
|
| Mouth Neoplasms | 3 | 2020 | 70 | 1.400 |
Why?
|
| Papillomavirus Vaccines | 6 | 2021 | 136 | 1.390 |
Why?
|
| Registries | 16 | 2023 | 330 | 1.350 |
Why?
|
| Mammary Glands, Human | 3 | 2018 | 39 | 1.340 |
Why?
|
| Adult | 58 | 2022 | 11034 | 1.330 |
Why?
|
| Anus Diseases | 5 | 2012 | 17 | 1.290 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2020 | 176 | 1.280 |
Why?
|
| Incidence | 24 | 2023 | 882 | 1.250 |
Why?
|
| Thyroid Neoplasms | 3 | 2020 | 35 | 1.230 |
Why?
|
| Cohort Studies | 29 | 2023 | 1422 | 1.210 |
Why?
|
| Risk Factors | 32 | 2023 | 3414 | 1.120 |
Why?
|
| Alphapapillomavirus | 7 | 2015 | 37 | 1.120 |
Why?
|
| Laryngeal Neoplasms | 3 | 2016 | 11 | 1.120 |
Why?
|
| DNA, Viral | 14 | 2019 | 295 | 1.100 |
Why?
|
| Male | 59 | 2023 | 18870 | 1.070 |
Why?
|
| Gene Expression | 4 | 2018 | 639 | 1.040 |
Why?
|
| Microcystins | 2 | 2023 | 8 | 1.030 |
Why?
|
| Survival Analysis | 12 | 2023 | 322 | 0.920 |
Why?
|
| Cervix Uteri | 6 | 2013 | 43 | 0.910 |
Why?
|
| Aged, 80 and over | 21 | 2021 | 2333 | 0.910 |
Why?
|
| United States | 31 | 2023 | 3894 | 0.900 |
Why?
|
| Bacterial Toxins | 1 | 2023 | 44 | 0.900 |
Why?
|
| Cystadenocarcinoma, Serous | 5 | 2022 | 33 | 0.880 |
Why?
|
| Case-Control Studies | 18 | 2023 | 1056 | 0.860 |
Why?
|
| Genitalia, Male | 3 | 2013 | 12 | 0.840 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 4 | 0.840 |
Why?
|
| Mouth | 1 | 2021 | 44 | 0.810 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2016 | 375 | 0.810 |
Why?
|
| Anus Neoplasms | 6 | 2019 | 47 | 0.790 |
Why?
|
| Areca | 2 | 2021 | 27 | 0.780 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 11 | 0.780 |
Why?
|
| Relaxin | 1 | 2020 | 10 | 0.780 |
Why?
|
| Hypothyroidism | 1 | 2020 | 18 | 0.770 |
Why?
|
| Specimen Handling | 3 | 2015 | 49 | 0.770 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 23 | 0.760 |
Why?
|
| Human papillomavirus 16 | 8 | 2021 | 34 | 0.760 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2018 | 29 | 0.760 |
Why?
|
| Prognosis | 14 | 2022 | 707 | 0.690 |
Why?
|
| SEER Program | 14 | 2023 | 87 | 0.690 |
Why?
|
| Vimentin | 1 | 2018 | 32 | 0.680 |
Why?
|
| Prevalence | 15 | 2021 | 1425 | 0.650 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 89 | 0.640 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 120 | 0.620 |
Why?
|
| Mutation | 3 | 2020 | 1023 | 0.610 |
Why?
|
| Mouth Diseases | 1 | 2017 | 6 | 0.610 |
Why?
|
| Melanoma | 4 | 2023 | 91 | 0.610 |
Why?
|
| Colorectal Neoplasms | 6 | 2022 | 413 | 0.610 |
Why?
|
| Vaccination | 2 | 2010 | 259 | 0.590 |
Why?
|
| Precancerous Conditions | 1 | 2017 | 81 | 0.560 |
Why?
|
| Saliva | 1 | 2017 | 97 | 0.560 |
Why?
|
| Genotype | 12 | 2021 | 641 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 592 | 0.540 |
Why?
|
| Prostatic Neoplasms | 5 | 2023 | 794 | 0.540 |
Why?
|
| Carcinoma | 3 | 2022 | 94 | 0.530 |
Why?
|
| Immunohistochemistry | 11 | 2019 | 859 | 0.530 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 3 | 0.530 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2015 | 3 | 0.530 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2015 | 22 | 0.520 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 66 | 0.510 |
Why?
|
| Neoplasm Staging | 10 | 2020 | 269 | 0.500 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2018 | 37 | 0.490 |
Why?
|
| Virus Diseases | 2 | 2022 | 21 | 0.490 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 247 | 0.490 |
Why?
|
| Young Adult | 16 | 2022 | 4012 | 0.480 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 11 | 0.480 |
Why?
|
| Micronutrients | 3 | 2010 | 42 | 0.480 |
Why?
|
| Self Administration | 1 | 2013 | 41 | 0.470 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2019 | 16 | 0.460 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 39 | 0.460 |
Why?
|
| Penile Neoplasms | 3 | 2015 | 14 | 0.450 |
Why?
|
| Adolescent | 17 | 2020 | 5035 | 0.450 |
Why?
|
| Antigens, Viral | 1 | 2012 | 42 | 0.440 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 151 | 0.430 |
Why?
|
| Anal Canal | 3 | 2010 | 28 | 0.430 |
Why?
|
| Virion | 1 | 2012 | 67 | 0.430 |
Why?
|
| Circumcision, Male | 2 | 2010 | 7 | 0.420 |
Why?
|
| Capsid Proteins | 1 | 2012 | 60 | 0.420 |
Why?
|
| Health Status Disparities | 3 | 2019 | 583 | 0.410 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2015 | 8 | 0.400 |
Why?
|
| Proportional Hazards Models | 12 | 2021 | 423 | 0.400 |
Why?
|
| Body Height | 2 | 2021 | 52 | 0.400 |
Why?
|
| Pancreatic Neoplasms | 4 | 2015 | 106 | 0.390 |
Why?
|
| Retrospective Studies | 9 | 2022 | 1961 | 0.380 |
Why?
|
| Health Promotion | 1 | 2016 | 588 | 0.380 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2022 | 123 | 0.380 |
Why?
|
| Penile Diseases | 1 | 2010 | 8 | 0.380 |
Why?
|
| Body Mass Index | 5 | 2021 | 775 | 0.380 |
Why?
|
| Sexual Behavior | 4 | 2021 | 587 | 0.380 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 252 | 0.370 |
Why?
|
| Mammography | 3 | 2018 | 176 | 0.370 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2021 | 165 | 0.360 |
Why?
|
| Odds Ratio | 6 | 2021 | 517 | 0.360 |
Why?
|
| Guam | 2 | 2021 | 76 | 0.350 |
Why?
|
| Postmenopause | 4 | 2014 | 125 | 0.350 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 2561 | 0.340 |
Why?
|
| Organ Transplantation | 4 | 2023 | 17 | 0.340 |
Why?
|
| Weight Gain | 1 | 2009 | 128 | 0.330 |
Why?
|
| Tissue Array Analysis | 8 | 2020 | 65 | 0.320 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 239 | 0.310 |
Why?
|
| Heterosexuality | 1 | 2008 | 85 | 0.310 |
Why?
|
| Tumor Virus Infections | 1 | 2007 | 25 | 0.310 |
Why?
|
| Keratins | 2 | 2018 | 25 | 0.310 |
Why?
|
| Immunocompromised Host | 3 | 2018 | 21 | 0.310 |
Why?
|
| Survival Rate | 4 | 2020 | 310 | 0.310 |
Why?
|
| Head and Neck Neoplasms | 2 | 2020 | 73 | 0.300 |
Why?
|
| Sexual Partners | 2 | 2008 | 308 | 0.300 |
Why?
|
| Liver Diseases | 3 | 2016 | 31 | 0.300 |
Why?
|
| Vulvar Neoplasms | 3 | 2016 | 12 | 0.290 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 203 | 0.280 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2023 | 25 | 0.280 |
Why?
|
| Physician's Role | 1 | 2006 | 34 | 0.270 |
Why?
|
| Longitudinal Studies | 6 | 2013 | 841 | 0.270 |
Why?
|
| Intermediate Filament Proteins | 1 | 2005 | 14 | 0.270 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2023 | 165 | 0.260 |
Why?
|
| Diet Surveys | 2 | 2009 | 96 | 0.250 |
Why?
|
| Self Care | 1 | 2006 | 150 | 0.250 |
Why?
|
| Keratin-7 | 2 | 2019 | 4 | 0.250 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2015 | 32 | 0.250 |
Why?
|
| MicroRNAs | 2 | 2020 | 386 | 0.250 |
Why?
|
| HIV Infections | 4 | 2022 | 2207 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2023 | 200 | 0.240 |
Why?
|
| Vitamin B Complex | 1 | 2003 | 5 | 0.240 |
Why?
|
| Privacy | 1 | 2023 | 7 | 0.240 |
Why?
|
| Phytoestrogens | 1 | 2004 | 35 | 0.240 |
Why?
|
| DNA Methylation | 3 | 2018 | 301 | 0.240 |
Why?
|
| Recurrence | 2 | 2021 | 125 | 0.240 |
Why?
|
| Gonorrhea | 1 | 2023 | 31 | 0.230 |
Why?
|
| BK Virus | 1 | 2023 | 5 | 0.230 |
Why?
|
| Marine Toxins | 1 | 2023 | 14 | 0.230 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2023 | 17 | 0.230 |
Why?
|
| Transcription Factors | 4 | 2022 | 653 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 964 | 0.230 |
Why?
|
| Polyomavirus Infections | 1 | 2023 | 20 | 0.230 |
Why?
|
| Early Detection of Cancer | 4 | 2019 | 292 | 0.230 |
Why?
|
| Stomach Neoplasms | 2 | 2021 | 192 | 0.230 |
Why?
|
| Prospective Studies | 8 | 2021 | 1353 | 0.220 |
Why?
|
| Biomedical Research | 2 | 2019 | 371 | 0.220 |
Why?
|
| Time Factors | 6 | 2015 | 1681 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 63 | 0.220 |
Why?
|
| Medicare | 2 | 2021 | 188 | 0.220 |
Why?
|
| Liver Transplantation | 2 | 2020 | 30 | 0.220 |
Why?
|
| Paraffin Embedding | 3 | 2021 | 12 | 0.220 |
Why?
|
| Tocopherols | 3 | 2013 | 62 | 0.210 |
Why?
|
| Formaldehyde | 3 | 2021 | 33 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2003 | 196 | 0.210 |
Why?
|
| Sepsis | 1 | 2022 | 76 | 0.210 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 17 | 0.210 |
Why?
|
| Chlamydia Infections | 1 | 2023 | 196 | 0.200 |
Why?
|
| Risk | 4 | 2015 | 256 | 0.200 |
Why?
|
| Drug Users | 1 | 2022 | 42 | 0.200 |
Why?
|
| Carotenoids | 3 | 2012 | 70 | 0.200 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 6 | 0.200 |
Why?
|
| Laboratories | 1 | 2021 | 36 | 0.200 |
Why?
|
| Asia | 1 | 2021 | 74 | 0.200 |
Why?
|
| Cystadenoma, Serous | 1 | 2020 | 1 | 0.190 |
Why?
|
| Endometriosis | 1 | 2022 | 69 | 0.190 |
Why?
|
| Organ Specificity | 1 | 2020 | 123 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2021 | 91 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 74 | 0.190 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 53 | 0.190 |
Why?
|
| Tissue Fixation | 2 | 2021 | 18 | 0.190 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2019 | 5 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 112 | 0.180 |
Why?
|
| Research | 1 | 2021 | 159 | 0.180 |
Why?
|
| Age Factors | 5 | 2020 | 1007 | 0.170 |
Why?
|
| Warts | 2 | 2011 | 5 | 0.170 |
Why?
|
| Prostate | 2 | 2023 | 136 | 0.170 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2013 | 38 | 0.170 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 13 | 0.170 |
Why?
|
| Behavioral Research | 1 | 2019 | 37 | 0.170 |
Why?
|
| Penis | 2 | 2010 | 72 | 0.170 |
Why?
|
| Receptor, erbB-2 | 2 | 2018 | 122 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2019 | 116 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 39 | 0.170 |
Why?
|
| Neutrophils | 1 | 2019 | 124 | 0.170 |
Why?
|
| Minority Health | 1 | 2019 | 81 | 0.170 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 10 | 0.160 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2018 | 8 | 0.160 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2020 | 14 | 0.160 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 15 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 74 | 0.160 |
Why?
|
| Metabolome | 1 | 2018 | 47 | 0.160 |
Why?
|
| Ovary | 1 | 2018 | 101 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2018 | 30 | 0.160 |
Why?
|
| Cause of Death | 2 | 2015 | 154 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 58 | 0.160 |
Why?
|
| Inflammation | 2 | 2020 | 577 | 0.150 |
Why?
|
| Actinomyces | 1 | 2017 | 5 | 0.150 |
Why?
|
| Streptococcus | 1 | 2017 | 13 | 0.150 |
Why?
|
| Mastication | 1 | 2017 | 19 | 0.150 |
Why?
|
| Vulva | 1 | 2016 | 3 | 0.150 |
Why?
|
| Food | 1 | 2018 | 95 | 0.150 |
Why?
|
| Hepatitis | 1 | 2016 | 10 | 0.140 |
Why?
|
| Benzamides | 2 | 2014 | 76 | 0.140 |
Why?
|
| Telomere | 1 | 2016 | 51 | 0.140 |
Why?
|
| Family Practice | 1 | 2016 | 43 | 0.140 |
Why?
|
| Sex Factors | 3 | 2016 | 859 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 133 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 25 | 0.130 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2015 | 2 | 0.130 |
Why?
|
| Logistic Models | 6 | 2014 | 894 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 86 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2015 | 58 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 23 | 0.130 |
Why?
|
| Coffee | 1 | 2014 | 20 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 781 | 0.130 |
Why?
|
| Photosensitizing Agents | 1 | 2015 | 47 | 0.130 |
Why?
|
| Vaginal Neoplasms | 1 | 2014 | 1 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 72 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 2015 | 116 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2017 | 628 | 0.120 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 82 | 0.120 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 149 | 0.120 |
Why?
|
| Calcifediol | 1 | 2014 | 14 | 0.120 |
Why?
|
| Minority Groups | 1 | 2019 | 537 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 2014 | 91 | 0.120 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2013 | 3 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2023 | 727 | 0.120 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2013 | 11 | 0.120 |
Why?
|
| Population Surveillance | 3 | 2017 | 231 | 0.120 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 13 | 0.120 |
Why?
|
| Parity | 1 | 2013 | 46 | 0.120 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 570 | 0.120 |
Why?
|
| Piperazines | 1 | 2014 | 109 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2014 | 112 | 0.120 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 23 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 33 | 0.120 |
Why?
|
| Comorbidity | 3 | 2016 | 606 | 0.120 |
Why?
|
| Hepacivirus | 1 | 2013 | 59 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2013 | 20 | 0.110 |
Why?
|
| Massachusetts | 2 | 2023 | 29 | 0.110 |
Why?
|
| Choline Kinase | 1 | 2012 | 2 | 0.110 |
Why?
|
| Hexokinase | 1 | 2012 | 9 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 13 | 0.110 |
Why?
|
| Adiponectin | 1 | 2013 | 52 | 0.110 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 20 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 44 | 0.110 |
Why?
|
| Samoa | 1 | 2012 | 17 | 0.110 |
Why?
|
| Neutralization Tests | 1 | 2012 | 53 | 0.110 |
Why?
|
| Microspheres | 1 | 2012 | 45 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 147 | 0.110 |
Why?
|
| Immunoassay | 1 | 2012 | 57 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 64 | 0.110 |
Why?
|
| Cytokinesis | 1 | 2011 | 11 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2012 | 47 | 0.110 |
Why?
|
| Leptin | 1 | 2013 | 115 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2012 | 118 | 0.100 |
Why?
|
| Condylomata Acuminata | 1 | 2011 | 6 | 0.100 |
Why?
|
| Hepatitis B | 2 | 2016 | 39 | 0.100 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 70 | 0.100 |
Why?
|
| Prions | 1 | 2011 | 25 | 0.100 |
Why?
|
| Los Angeles | 4 | 2014 | 368 | 0.100 |
Why?
|
| Poisson Distribution | 3 | 2015 | 39 | 0.100 |
Why?
|
| Vaginal Smears | 2 | 2017 | 52 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 445 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2014 | 418 | 0.100 |
Why?
|
| Foreskin | 1 | 2010 | 4 | 0.100 |
Why?
|
| Confidence Intervals | 3 | 2016 | 151 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2014 | 486 | 0.090 |
Why?
|
| Tissue Banks | 2 | 2011 | 5 | 0.090 |
Why?
|
| Mice | 6 | 2018 | 5668 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 790 | 0.090 |
Why?
|
| Hepatitis C | 2 | 2016 | 120 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 220 | 0.090 |
Why?
|
| Proctitis | 1 | 2009 | 2 | 0.090 |
Why?
|
| Cytokines | 1 | 2013 | 569 | 0.090 |
Why?
|
| Receptors, Progesterone | 3 | 2020 | 78 | 0.090 |
Why?
|
| Animals | 8 | 2018 | 14307 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 2128 | 0.080 |
Why?
|
| Protein Array Analysis | 2 | 2005 | 26 | 0.080 |
Why?
|
| Smoking | 3 | 2017 | 903 | 0.080 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 65 | 0.080 |
Why?
|
| Soy Foods | 1 | 2009 | 59 | 0.080 |
Why?
|
| Disease Transmission, Infectious | 1 | 2008 | 29 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1152 | 0.080 |
Why?
|
| Nutritional Status | 1 | 2009 | 114 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2017 | 1349 | 0.080 |
Why?
|
| Semen | 1 | 2008 | 48 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 184 | 0.080 |
Why?
|
| Breast | 1 | 2009 | 134 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2020 | 420 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 531 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 446 | 0.080 |
Why?
|
| Condoms | 1 | 2008 | 132 | 0.080 |
Why?
|
| California | 2 | 2021 | 436 | 0.070 |
Why?
|
| Vitamin A | 1 | 2007 | 87 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 522 | 0.070 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 115 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 756 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 211 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2016 | 490 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2018 | 323 | 0.070 |
Why?
|
| Epidemiologic Research Design | 1 | 2005 | 16 | 0.070 |
Why?
|
| Keratin-20 | 1 | 2005 | 2 | 0.070 |
Why?
|
| Herpesviridae Infections | 1 | 2005 | 18 | 0.070 |
Why?
|
| Sarcoma, Kaposi | 1 | 2005 | 20 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 484 | 0.070 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 15 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 114 | 0.070 |
Why?
|
| Social Marketing | 1 | 2004 | 22 | 0.060 |
Why?
|
| Mass Media | 1 | 2004 | 31 | 0.060 |
Why?
|
| Receptors, Estrogen | 2 | 2020 | 145 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 1003 | 0.060 |
Why?
|
| Thiamine | 1 | 2003 | 6 | 0.060 |
Why?
|
| Women's Health | 1 | 2004 | 135 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 386 | 0.060 |
Why?
|
| Riboflavin | 1 | 2003 | 24 | 0.060 |
Why?
|
| Hydroxycholesterols | 1 | 2023 | 12 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 2003 | 19 | 0.060 |
Why?
|
| Confidentiality | 1 | 2023 | 26 | 0.060 |
Why?
|
| Iowa | 2 | 2016 | 8 | 0.060 |
Why?
|
| Mortality | 1 | 2005 | 150 | 0.060 |
Why?
|
| Folic Acid | 1 | 2003 | 46 | 0.060 |
Why?
|
| Patient Selection | 1 | 2004 | 154 | 0.060 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2023 | 8 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2023 | 24 | 0.060 |
Why?
|
| Aneuploidy | 2 | 2014 | 20 | 0.060 |
Why?
|
| Biopsy | 1 | 2003 | 151 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 18 | 0.060 |
Why?
|
| Cyclin E | 1 | 2022 | 13 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2023 | 188 | 0.060 |
Why?
|
| Glycolysis | 1 | 2023 | 66 | 0.060 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2022 | 22 | 0.060 |
Why?
|
| Universities | 1 | 2006 | 363 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 95 | 0.060 |
Why?
|
| Testosterone | 1 | 2023 | 181 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 1530 | 0.050 |
Why?
|
| Trust | 1 | 2023 | 119 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 9 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 74 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 555 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 146 | 0.050 |
Why?
|
| Genomics | 1 | 2023 | 201 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 1300 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 469 | 0.050 |
Why?
|
| Harm Reduction | 1 | 2022 | 20 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2012 | 143 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 121 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2021 | 32 | 0.050 |
Why?
|
| Housing | 1 | 2022 | 54 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2021 | 44 | 0.050 |
Why?
|
| Pathology | 1 | 2021 | 7 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 150 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 105 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 13 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2021 | 288 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 46 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 155 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 901 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2014 | 878 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 287 | 0.050 |
Why?
|
| Appendiceal Neoplasms | 1 | 2019 | 3 | 0.050 |
Why?
|
| Body Weight | 1 | 2021 | 404 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 122 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2009 | 42 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 600 | 0.040 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2018 | 9 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Overweight | 1 | 2021 | 233 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 52 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2018 | 125 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 336 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2018 | 65 | 0.040 |
Why?
|
| Computational Biology | 1 | 2020 | 275 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2018 | 121 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 211 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 2018 | 77 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2018 | 38 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2021 | 435 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 133 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 158 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 37 | 0.040 |
Why?
|
| Metabolomics | 1 | 2018 | 76 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2019 | 182 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2017 | 29 | 0.040 |
Why?
|
| Micronesia | 1 | 2017 | 87 | 0.040 |
Why?
|
| Algorithms | 1 | 2020 | 435 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 35 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 109 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 51 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2017 | 115 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 649 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 18 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2018 | 226 | 0.040 |
Why?
|
| Central America | 1 | 2016 | 9 | 0.040 |
Why?
|
| South America | 1 | 2016 | 16 | 0.040 |
Why?
|
| Demography | 1 | 2016 | 167 | 0.040 |
Why?
|
| Latin America | 1 | 2016 | 41 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2016 | 70 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 608 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 112 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 110 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 36 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 223 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 18 | 0.030 |
Why?
|
| Azathioprine | 1 | 2015 | 5 | 0.030 |
Why?
|
| Florida | 1 | 2016 | 358 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2015 | 26 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2016 | 323 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 179 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 31 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 20 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 154 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 59 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2014 | 9 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 295 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 41 | 0.030 |
Why?
|
| Cell Division | 1 | 2015 | 296 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 49 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 455 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 292 | 0.030 |
Why?
|
| Myosin Type II | 1 | 2014 | 18 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 468 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2014 | 72 | 0.030 |
Why?
|
| Sunlight | 1 | 2014 | 46 | 0.030 |
Why?
|
| Mass Screening | 1 | 2017 | 427 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 580 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 121 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2013 | 13 | 0.030 |
Why?
|
| Genes, myc | 1 | 2013 | 28 | 0.030 |
Why?
|
| Tanzania | 1 | 2013 | 7 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 296 | 0.030 |
Why?
|
| RNA | 1 | 2015 | 234 | 0.030 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 14 | 0.030 |
Why?
|
| Bacteria | 1 | 2016 | 245 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 22 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 2012 | 16 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2012 | 45 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 47 | 0.030 |
Why?
|
| Microscopy | 1 | 2012 | 32 | 0.030 |
Why?
|
| Life Style | 1 | 2014 | 288 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 834 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 416 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2012 | 79 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 87 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 650 | 0.030 |
Why?
|
| Triglycerides | 1 | 2012 | 129 | 0.030 |
Why?
|
| Oncogenes | 1 | 2011 | 43 | 0.030 |
Why?
|
| Quinazolines | 1 | 2011 | 31 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 545 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2013 | 287 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 424 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 52 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 406 | 0.030 |
Why?
|
| Cholesterol | 1 | 2012 | 194 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 430 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 222 | 0.020 |
Why?
|
| Mitosis | 1 | 2011 | 97 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 465 | 0.020 |
Why?
|
| Chromatin | 1 | 2011 | 164 | 0.020 |
Why?
|
| Histones | 1 | 2011 | 177 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 309 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 871 | 0.020 |
Why?
|
| Obesity | 1 | 2018 | 965 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 1802 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 1014 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 490 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 37 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 32 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 61 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1318 | 0.020 |
Why?
|
| Premenopause | 1 | 2009 | 103 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2009 | 105 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 1503 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 298 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 171 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 747 | 0.020 |
Why?
|
| Child | 1 | 2013 | 2875 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 3261 | 0.020 |
Why?
|
| Aging | 1 | 2009 | 639 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1149 | 0.010 |
Why?
|
| Motivation | 1 | 2004 | 415 | 0.010 |
Why?
|